ACQUISITIONS, DIVESTITURES AND LICENSING ARRANGEMENTS (Tables)

12 Months Ended

Dec. 31, 2018

Acquisitions and Divestitures [Abstract]

Schedule of Asset Acquisitions, by Acquisition [Table Text Block]

Dollars in Millions	Year	Upfront Payment		R&D Expense		Deferred Tax Assets(a)		Contingent Consideration
IFM(b)	2017	$	325	$	311	$	14	$	2,020
Cormorant	2016	35		35		—		485
Padlock	2016	150		139		11		453

(a) Relates to net operating loss and tax credit carryforwards.

(b) Includes $25 million for certain negotiation rights to collaborate, license or acquire an NLRP3 antagonist program from a newly formed entity established by the former shareholders of IFM.

Divestitures [Table Text Block]

Divestitures

The following table summarizes proceeds, gains and royalty income resulting from divestitures. Revenue and pretax earnings related to all divestitures and assets held-for-sale were not material in all periods presented (excluding divestiture gains).

	Proceeds(a)						Divestiture Gains									Royalty Income
Dollars in Millions	2018		2017		2016		2018			2017			2016			2018			2017			2016
Diabetes Business	$	579	$	405	$	333	$	—		$	(126	)	$	—		$	(661	)	$	(329	)	$	(361	)
Erbitux* Business	216		218		252		—			—			—			(145		)	(224		)	(246		)
Manufacturing Operations	160		—		—		—			—			—			—			—			—
Plavix* and Avapro*/Avalide*	80		—		—		—			—			—			—			—			—
Investigational HIV Business	—		—		387		—			(11		)	(272		)	—			—			—
OTC Business	—		—		317		—			—			(277		)	—			—			—
Mature Brands and Other	212		28		28		(178		)	(24		)	(15		)	(8		)	(4		)	(11		)
	$	1,247	$	651	$	1,317	$	(178	)	$	(161	)	$	(564	)	$	(814	)	$	(557	)	$	(618	)

(a) Includes royalties received subsequent to the related sale of the asset or business.